Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Study Protocol for a Randomized Phase II Trial Full Text
BMC Cancer, 08/09/2012
Palma DA et al. – This study will provide an assessment of the impact of Stereotactic ablative radiotherapy (SABR) on clinical outcomes and quality of life, to determine if long–term survival can be achieved for selected patients with oligometastatic disease, and will inform the design of a possible phase III study.



